Cardiff, Wales, UK, 01 March 2023: Antiverse Ltd (Antiverse), a biotechnology company developing a computational antibody drug discovery platform, today announced the successful identification of functional antibody clusters targeting two G-protein-coupled receptors (GPCRs), both displaying versatile binding Read More
Tags :Tensor Ventures
Antiverse raises £1.4 million ($2 million USD) to advance its AI antibody drug discovery platform · Funding will accelerate development of the Company’s AI-powered antibody drug discovery technology, Read More